DWP
VKTX icon

Daymark Wealth Partners’s Viking Therapeutics VKTX Stock Holding History

Daymark Wealth Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Hold
8,000
– – 0.01% 618
2026
Q1 		$260K Buy
+8,000
New +$257K 0.01% 622
2025
Q4 		– Sell
-8,000
Closed -$210K – 632
2025
Q3 		$210K Hold
8,000
– – 0.01% 582
2025
Q2 		$212K Buy
+8,000
New +$211K 0.01% 528

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Daymark Wealth Partners's VKTX Position: Q2 2026 in Review

Daymark Wealth Partners held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 8,000 shares worth $312K. The position accounts for 0.01% of the portfolio, ranked #618.

Daymark Wealth Partners first reported a position in VKTX in Q2 2025 and has held it in 4 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Daymark Wealth Partners held 8,000 shares of Viking Therapeutics worth $312K as of Q2 2026.
  • Daymark Wealth Partners left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.01% of Daymark Wealth Partners's portfolio in Q2 2026, its #618 holding.
  • Daymark Wealth Partners first reported a position in Viking Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.